Needham & Company analyst, Stephen Unger, reiterated his Buy on Neogenomics (NASDAQ: NEO) and raised his price target to $22.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE